Skip to main content
. 2019 Sep 17;11:8463–8473. doi: 10.2147/CMAR.S221877

Figure 4.

Figure 4

EGFR inhibitor promotes phosphorylation of Stat3 in pancreatic cancer cells. The EGFR inhibitor (erlotinib, gefitinib, afatinib and cetuximab) was used to treat the PANC-1 and BxPC-3 cells at the concentration of 20 nM. (A) The mRNA and (B) protein expressions of EGFR were detected with qRT-PCR and Western blotting, respectively. (C) And the protein expression of p-Stat3 was detected with Western blotting.